Phase-I study of Innacell γδ™, an autologous cell-therapy product highly enriched in γ9δ2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma (Q57949352)
Jump to navigation
Jump to search
scientific article published on 27 February 2008
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Phase-I study of Innacell γδ™, an autologous cell-therapy product highly enriched in γ9δ2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma |
scientific article published on 27 February 2008 |
Statements
Phase-I study of Innacell gammadelta, an autologous cell-therapy product highly enriched in gamma9delta2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma (English)
Jaafar Bennouna
Emmanuelle Bompas
Eve Marie Neidhardt
Irène Philip
Céline Galéa
Samuel Salot
Soraya Saiagh
Marie Audrain
Marie Rimbert
Sylvie Lafaye-de Micheaux
Jérôme Tiollier
Sylvie Négrier
27 February 2008
1 reference
1 reference